Thera-SAbDab

SETRUSUMAB

>   Structural Summary
TherapeuticSetrusumab
TargetSOST
Heavy ChainQVQLVESGGGLVQPGGSLRLSCAASGFTFRSHWLSWVRQAPGKGLEWVSNINYDGSSTYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARDTYLHFDYWGQGTLVTVSS
Light ChainDIALTQPASVSGSPGQSITISCTGTSSDVGDINDVSWYQQHPGKAPKLMIYDVNNRPSGVSNRFSGSKSGNTASLTISGLQAEDEADYYCQSYAGSYLSEVFGGGTKLTVL
100% seqID Fv StructureNone
99% seqID Fv StructureNone
95-98% seqID Fv StructureNone
>   Metadata
FormatWhole mAb
IsotypeG2
Highest Clinical Trial (June '19)Phase-II
Estimated Status (June '19)Active
Recorded Developmental TechnologyMorphoSys HuCAL Phage Display
INN Year Proposed2017
INN Year Recommended2018
Companies InvolvedMorphoSys, Novartis, Mereo BioPharma
Conditions Approvedna
Conditions ActiveOsteogenesis imperfecta
Conditions DiscontinuedHypophosphatasia, Postmenopausal osteoporosis
Notes

SAbDab paper: Dunbar, J., Krawczyk, K. et al (2014). Nucleic Acids Res. 42. D1140-D1146 [link]

Thera-SAbDab paper: Raybould, M.I.J., Marks, C. et al (2019). Nucleic Acids Res. gkz827 [link]